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Objectives: It is important to ascertain which
anthropometric measurements of obesity, general or
central, are better predictors of cardiovascular disease
(CVD) risk in women. 10-year CVD risk was calculated
from the Framingham risk score model, SCORE risk
chart for high-risk regions, general CVD and simplified
general CVD risk score models. Increase in CVD risk
associated with 1 SD increment in each anthropometric
measurement above the mean was calculated, and the
diagnostic utility of obesity measures in identifying
participants with increased likelihood of being above
the treatment threshold was assessed.
Design: Cross-sectional data from the National Heart
Foundation Risk Factor Prevalence Study.
Setting: Population-based survey in Australia.
Participants: 4487 women aged 20–69 years without
heart disease, diabetes or stroke.
Outcome measures: Anthropometric obesity
measures that demonstrated the greatest increase in
CVD risk as a result of incremental change, 1 SD above
the mean, and obesity measures that had the greatest
diagnostic utility in identifying participants above the
respective treatment thresholds of various risk score
models.
Results: Waist circumference (WC), waist-to-hip ratio
(WHR) and waist-to-stature ratio had larger effects on
increased CVD risk compared with body mass index
(BMI). These central obesity measures also had higher
sensitivity and specificity in identifying women above
and below the 20% treatment threshold than BMI.
Central obesity measures also recorded better
correlations with CVD risk compared with general
obesity measures. WC and WHR were found to be
significant and independent predictors of CVD risk, as
indicated by the high area under the receiver operating
characteristic curves (>0.76), after controlling for BMI
in the simplified general CVD risk score model.
Conclusions: Central obesity measures are better
predictors of CVD risk compared with general obesity
measures in women. It is equally important to maintain
a healthy weight and to prevent central obesity
concurrently.
INTRODUCTION
In 2008, more than 200 million men and
approximately 300 million women were
obese.1 Overweight and obesity is one of the
leading risk factors for mortality, estimated to
account for 23% of the ischaemic heart
disease burden.1 It results in the deterior-
ation of the entire cardiovascular risk
profile.2 3 Large prospective studies such as
the Framingham Heart Study,4 the Nurses’
Health Study5 6 and the Buffalo Health
Study7 have all shown that overweight and
obesity are associated with increased cardio-
vascular disease (CVD) risk. Excess adipose
tissue contributes to the cardiovascular and
other risks associated with being overweight
or obese.8
Strengths and limitations of this study
▪ This study provided evidence that anthropomet-
ric measures of central obesity are better predic-
tors of cardiovascular disease (CVD) risk
compared with general obesity measures in
women.
▪ Central obesity measures add prognostic infor-
mation on CVD risk in women above the mea-
sures of general obesity and should be
considered for incorporation into the clinical
assessment of CVD risk.
▪ Although this study is cross-sectional, it is a rep-
resentative sample of the Australian female
population.
▪ Only one set of baseline measurements is
recorded for some risk variables but some
important variables are measured twice.
▪ The predicted 10-year CVD risks are calculated
using risk score models to stratify individuals
against the treatment thresholds for various risk
score models. Prospective data of CVD events
were not used.
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The American Heart Association released a Scientific
Statement emphasising the importance of assessing adi-
posity.8 New guidelines have also been released by the
American College of Cardiology, American Heart
Association Task Force on Practice Guidelines and The
Obesity Society for the management of overweight and
obesity in adults to prevent CVD.9 General and central
obesity are associated with CVD risk.5 10–15 Currently
used general and central obesity anthropometric mea-
sures for assessing adiposity-related risk include: body
mass index (BMI; weight in kilograms divided by square
of height in meters), waist circumference (WC), hip cir-
cumference (HC), waist-to-hip ratio (WHR; ratio of WC
to HC), waist-to-stature ratio (WSR; ratio of WC to
height) and body adiposity index16 (BAI; HC divided by
height1.5, and subtracting 18 from the result). BMI or
WC is most commonly used to measure body fatness.10
It is, however, unclear which anthropometric measure-
ments are better correlated with CVD risk factors and
CVD risk in women, considering adiposity is highly het-
erogeneous with age, sex and ethnic differences in body
fat distribution.8 Previous studies have reported that BMI
identified individuals at increased risk of CVD as effect-
ively as WC.11 12 It has also been suggested that BMI is a
better predictor of CVD than WC.13 Conversely, some
studies reported that WC is a better indicator of CVD
risk than BMI and WHR, in ethnically diverse
groups.14 15 WC and WHR have also been identified as
independent predictors of CVD risk but not BMI,
accounting for conventional risk factors in the
Framingham risk score model.17 More research is thus
needed to ascertain which measures are better corre-
lated with CVD risk factors and subsequent CVD risk in
women.
We aim to assess the associations between general and
central obesity anthropometric measures with CVD risk
factors, using a representative sample of 4487 women
aged 20–69 years without heart disease, diabetes or
stroke. The associations between these indices of obesity
with predicted risk calculated from the Framingham risk
score model for 10-year CVD incidence or death,18
SCORE risk chart for high-risk regions for 10-year CVD
death,19 general CVD and simplified general CVD risk
score models for 10-year CVD incidence and death20
were examined. To aid comparison between obesity
indices, which are measured in different units, the incre-
mental shift in CVD risk with 1 SD increment in each
anthropometric measurement above the mean would be
assessed. Finally, we determined which indices of obesity
are most sensitive and specific for identifying women at
increased 10-year CVD risk.
METHODS
Study cohort and measurements
We selected 4487 women aged 20–69 years with no
history of heart disease, diabetes or stroke from the
population representative sample of 4727 women from
the National Heart Foundation (NHF) Risk Factor
Prevalence Study.21 Participants taking medications to
lower their CVD risk factors were also excluded. The
participants of the NHF study consisted of residents on
the federal electoral rolls of December 1988 in North
and South Sydney, Melbourne, Brisbane, Adelaide,
Perth, Hobart, Darwin and Canberra in a systematic
probability sampling by sex and 5-year age groups.
Information on demographic characteristics was col-
lected using a self-administered questionnaire, and con-
ventional CVD risk variables recorded in this prevalence
study include anthropometric measures, smoking status,
systolic and diastolic blood pressure and lipid levels.
Physical measurements of height (to the nearest centi-
metre), weight (to the nearest 10th of a kilogram) and
waist and HC were collected according to standardised
methodologies22 23 using two observers. The WC was
measured from the front at the narrowest point between
the rib cage and iliac crest after full expiration while the
HC was measured from the side at the maximal exten-
sion of buttocks by one observer using a metal tape. A
second observer recorded another set of measurements
and ensured that the metal tape was kept strictly hori-
zontal at all times. The mean of two measurements was
taken at each site to the nearest centimetre. Participants
were classified as non-smokers, previous smokers or
current smokers.21 Mercury sphygmomanometers were
used to record blood pressure levels on the right arm of
seated participants 5 min apart.21 Two readings were
taken and the average was used in the analysis. Fasting
blood samples were also collected in EDTA tubes and
dispatched to the central laboratory at the Division of
Clinical Chemistry, Institute of Medical and Veterinary
Science, Adelaide each week for lipid levels to be
assayed.21
Risk score models
The Framingham 10-year predicted risk for CVD inci-
dence or death was developed using data from the
American Framingham Heart Study.18 Participants aged
30–74 years who were free of CVD and cancer were
included in the model development. The 10-year risk
for CVD incidence or death was calculated using these
variables: age, sex, systolic blood pressure (SBP), dia-
stolic blood pressure, total cholesterol level, high-density
lipoprotein (HDL) cholesterol level, smoking status and
diabetes status. The SCORE risk chart was developed by
pooling 12 cohort studies to predict the 10-year CVD
death risk in Europe. The cohorts consisted of partici-
pants aged 19–80 years with no previous history of heart
attack.19 The SCORE model was derived from a much
larger dataset than the Framingham, general CVD and
simplified general CVD risk score models. Fewer vari-
ables were used in the calculation of the 10-year pre-
dicted CVD death risk with the SCORE risk chart for
high-risk regions (Denmark, Finland and Norway),19 24
these included: age, sex, smoking status, mean total
cholesterol level, mean HDL cholesterol level and mean
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SBP. The general CVD risk score model was also devel-
oped using data from the American Framingham Heart
Study but using a larger cohort than the Framingham
model.20 Individuals without CVD were used in the
development of the general CVD risk score model.20
The simplified general CVD risk score model was devel-
oped similarly as the general CVD risk score model. It is,
however, a simpler CVD risk prediction model which is
calculated using non-laboratory predictors. Risk variables
(age, SBP, current antihypertensive treatment, smoking
status and diabetes status) were used in both models.20
The only difference is that, BMI is included in the sim-
plified general CVD risk score model instead of total
and HDL cholesterol which is used in the general CVD
risk score model.
Statistical analysis
The data on the representative sample of 4487
Australian women were described using mean±SD for
continuous variables, while counts and percentages were
used for categorical variables. Non-parametric
Spearman’s rank correlation was used to assess the asso-
ciations between anthropometric measurements of
obesity with CVD risk factors, and with the calculated
10-year predicted risks, due to the skewness in the distri-
bution of some variables. Anthropometric measure-
ments were also converted to z-scores (original value
subtracted by the mean and result divided by the SD) to
represent the number of SDs above and below the mean
for each participant. Logistic regression was used to
assess the effects of each standardised anthropometric
measurement of being above the recommended treat-
ment thresholds for various risk score models as a result
of 1 SD increment above the mean for each anthropo-
metric measure of obesity. ORs and associated 95% CIs
represented the likelihood of being above the recom-
mended treatment thresholds for the specific risk score
models (20% for the Framingham risk score model for
10-year CVD incidence or death; 10% for SCORE risk
chart for high-risk regions for 10-year CVD death; 10%
and 20% for the general CVD and simplified general
CVD risk score models for 10-year CVD incidence and
death). The predictive ability of these anthropometric
measures to identify individuals above and below the
Table 1 Characteristics of a representative Australian
sample of 4487 women (aged 20–69 years) free of heart












UK and Ireland 416 (9.5%)
Northern Europe 180 (4.1%)
Southern Europe 234 (5.4%)
Asia 195 (4.5%)
Smoking status, n (%)
Non-smoker 2652 (59.1)
Previous smoker 880 (19.6)
Current smoker 955 (21.3)
SBP (mm Hg) 122.1±18.4
DBP (mm Hg) 75.7±10.8
Total cholesterol (mmol/L) 5.5±1.2
HDL cholesterol (mmol/L) 1.5±0.4









BMI, body mass index; BAI, body adiposity index; DBP, diastolic
blood pressure; HC, hip circumference; HDL cholesterol,
high-density lipoprotein cholesterol; SBP, systolic blood pressure
WC, waist circumference; WHR, waist-to-hip ratio; WSR,
waist-to-stature ratio.
Table 2 Frequency distribution of 10-year predicted CVD incidence and mortality using various risk prediction models, in
incremental risk categories of 10%
Risk categories
0–9% 10–19% 20–29% 30–39% ≥40%
Framingham 10-year predicted risk for CVD incidence18 2936 (67.0%) 764 (17.4%) 417 (9.5%) 179 (4.1%) 89 (2.0%)
Framingham 10-year predicted risk for CVD death18 4354 (99.3%) 29 (0.7%) 2 (0%) 0 (0%) 0 (0%)
SCORE-HIGH 10-year predicted risk for CVD death19 4318 (98.5%) 53 (1.2%) 9 (0.2%) 4 (0.1%) 1 (0%)
GCVD 10-year predicted risk for CVD incidence and
death20
3738 (85.2%) 503 (11.5%) 109 (2.5%) 21 (0.5%) 14 (0.3%)
SGCVD 10-year predicted risk for CVD incidence and
death20
3809 (85.7%) 519 (11.7%) 90 (2.0%) 19 (0.4%) 9 (0.2%)
Counts and percentages of women were presented.
CVD, cardiovascular disease; GCVD, general cardiovascular disease risk score model; SCORE-HIGH, SCORE risk chart for high-risk
regions; SGCVD, simplified general cardiovascular disease risk score model.
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treatment thresholds was assessed using sensitivity, speci-
ficity and area under the receiver operating characteris-
tic (ROC) curve. p Values of less than 0.05 were
considered to be statistically significant. All statistical
analyses were performed with IBM SPSS Statistics V.21.
RESULTS
The sample of 4487 women aged 20–69 years from the
NHF Risk Factor Prevalence Study is a representative
sample of the Australian female population, free of
heart disease, diabetes and stroke. The characteristics of
the sample are summarised in table 1. In addition to the
conventional risk factors for CVD, all anthropometric
measurements of general and central obesity were
presented.
The 10-year CVD risk of each participant in the
sample was calculated using four risk score models. The
frequency distribution of calculated risks is presented in
table 2. Except for the Framingham model for CVD inci-
dence, all other models predicted risks of less than 10%
for at least 85% of the sample. The Framingham model
for CVD incidence, general CVD model for CVD inci-
dence and death and simplified general CVD model for
CVD incidence and death predicted risk values across
the entire range from 0% to greater than 40%.
Anthropometric measurements of obesity were posi-
tively correlated with age, SBP, total cholesterol and total
cholesterol to HDL cholesterol ratio (all Spearman’s
r ≥0.195, p<0.001), with HC recording the lowest corre-
lations. These obesity measures were negatively corre-
lated with HDL cholesterol (all Spearman’s r ≤–0.160,
p<0.001). Measures of central obesity that included a
measure of WC (WHR and WSR) generally recorded
better correlations compared with measures of general
obesity (BMI and BAI).
The associations between anthropometric measure-
ments of obesity and the 10-year predicted risks calcu-
lated using the four models are presented in table 3. All
Spearman’s rank correlations were statistically significant
(p<0.0005). All anthropometric measures of central
obesity (WC, WHR and WSR) generally had consistently
higher correlations with the predicted risks calculated
using the four CVD risk score models, as compared with
measures of general obesity.
Recommended treatment thresholds for the four CVD
risk models were identified from a review of the litera-
ture. Table 4 presents the effects of 1 SD increment in
each anthropometric measurement above the mean on
the likelihood of being above the recommended thresh-
olds or being indicated for treatment. All anthropomet-
ric measures of central obesity (WC, WHR and WSR)
generally recorded higher ORs than general measures
of obesity and they increased the likelihood of indivi-
duals being above the respective treatment thresholds.
Anthropometric measurements of central obesity
(WC, WHR and WSR) also recorded higher area under
the ROC curves, higher sensitivity and specificity, than
BMI in identifying women above and below the 20%
treatment threshold for the Framingham model for
10-year CVD incidence (figure 1A) and general CVD
model for 10-year CVD incidence and death (figure
1B). Although BMI is included in the simplified general
CVD model, high area under the ROC curve (>0.76) are
reported for WC and WHR (figure 1C), indicating the
independent contribution of central obesity measure-
ments as compared with general obesity measurement
in predicting the increased risk of CVD.
DISCUSSION
Measures of obesity are generally not included in the
prediction of CVD risk. BMI is the only measure of
obesity currently included in CVD risk score models
such as the simplified general CVD risk score model, as
an alternative to total and HDL cholesterol level for ease
of measurement and calculation,20 and in the QRISK
score model.29
In our study, anthropometric measurements of central
obesity (WC, WHR and WSR) were more strongly asso-
ciated with conventional CVD risk factors and the
10-year predicted risk calculated using the Framingham
risk score model, SCORE risk chart for high-risk regions,
general CVD and simplified general CVD risk score
Table 3 Non-parametric correlations between anthropometric measurements of general and central obesity and 10-year
predicted risk of CVD incidence and mortality in 4487 women
BMI WC HC WHR WSR BAI
Framingham 10-year predicted risk for CVD incidence18 0.380 0.450 0.301 0.409 0.485 0.378
Framingham 10-year predicted risk for CVD death18 0.394 0.452 0.307 0.404 0.483 0.377
SCORE-HIGH 10-year predicted risk for CVD death19 0.309 0.381 0.253 0.348 0.419 0.338
GCVD 10-year predicted risk for CVD incidence and death20 0.385 0.452 0.307 0.405 0.487 0.383
SGCVD 10-year predicted risk for CVD incidence and death20 * 0.446 0.320 0.384 * *
All Spearman’s rank correlations significant at the p<0.0005 level.
*Correlation is not calculated for this obesity measure as it contains variables that are also used in the calculation of the simplified general
CVD model.
BMI, body mass index; BAI, body adiposity index; CVD, cardiovascular disease; GCVD, general cardiovascular disease risk score model;
HC, hip circumference; WC, waist circumference; SCORE-HIGH, SCORE risk chart for high-risk regions; SGCVD, simplified general
cardiovascular disease risk score model; WHR, waist-to-hip ratio; WSR, waist-to-stature ratio.
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model, compared with general measures of obesity.
Central obesity measures also recorded higher ORs and
increased the likelihood of being above the recom-
mended treatment threshold of the respective models
with 1 SD increase above the mean. Central obesity mea-
sures which incorporated the measure of WC also exhib-
ited higher sensitivity and specificity than BMI.
Although BMI is included in the calculation of the sim-
plified general CVD model, high area under the ROC
curves were reported for WC and WHR, thus confirming
that anthropometric measures of central obesity inde-
pendently and significantly predicts CVD risk that is not
accounted for by the general obesity measure. Hence,
BMI alone is insufficient to account for the association
between obesity and CVD risk.
Consistent with our study findings, previous studies also
reported stronger associations between central obesity mea-
sures and CVD risk. Higher standardised ORs adjusted for
BMI were reported for WC and CVD, compared with BMI,
in women from the International Day for the Evaluation of
Abdominal Obesity (IDEA) study.30 31 An increase in WC
was associated with being 4.25 times more likely of stroke
and transient ischaemic attacks.32 Conversely, some studies
reported that the association between BMI and CVD was
similar to measures of central obesity.33 34
There are several possible explanations for our study
findings that measures of central obesity are better pre-
dictors of CVD risk than BMI. Greater central obesity is
associated with systemic inflammation which directly
contributes to CVD risk.35 Hence, measures that account
for the accumulation of excess abdominal fat would
report stronger associations and are desirable for asses-
sing adiposity. They would also be more accurate at indi-
cating CVD risk and should be incorporated into CVD
assessment.36–39 The addition of central obesity mea-
sures to BMI has also been shown to improve the accur-
acy of stratifying participants into lower and higher risk
categories for mortality40 and provides incremental
value in predicting CVD above and beyond that pro-
vided by general obesity measures.41–45 BMI is a flawed
measure as it does not correctly identify individuals with
excess body fat due to its inability to differentiate fat and
fat-free mass and it does not account for the effect of
age and ethnicity on body fat distribution.46–50 An
increase in muscle or fat-free mass would, however, be
reflected in the central obesity measures.
Among central obesity measures, we found their per-
formance to be comparable in our study. It remains
unclear which measurement should be incorporated into
CVD risk score models. A collaborative analysis of 58 pro-
spective studies, however, reported that measures of
general and central obesity did not improve CVD risk
assessment when information is available on SBP, diabetes
and lipids.51 Overweight and obesity are, nevertheless,
important in CVD prevention, with one of three fatal and
one of seven non-fatal CVD cases attributable to it.34
Opinion remains divided as to which is a more appropri-
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with CVD risk.37 Some studies recommended the use of
WC in clinical assessment and research studies.52 53 In a
systematic review and meta-analysis study of Caucasians
without CVD, WC was most highly correlated with all CVD
risk factors, compared with BMI, WHR, WSR and body fat
percentage, in women.52 In other studies, WC was also
more closely associated with CVD risk factors than other
measures of central obesity and BMI in women.54–57 The
advantages of WC are: it is easy to measure and interpret
and it is less prone to measurement and calculation
error.53 Appropriate sex, age and ethnic-specific WC cut-
points would need to be established.44 It would also be dif-
ficult to use WC in today’s multicultural societies due to
requirements for different cut-points.50
The use of WHR is also supported as it is less strongly
associated with BMI than WC, and is thus a more spe-
cific surrogate for fat distribution.40 A longitudinal
population study on 1462 women from Sweden reported
stronger relations between WHR and CVD endpoints,
compared with BMI, WC and HC.58 These relations
were mostly independent of age, BMI and either SBP,
cholesterol level or smoking habit.58 In a
meta-regression analysis of prospective studies, WHR was
also more strongly associated with CVD compared with
WC, although the difference was not significant.37
Another study reported that WHR was associated with
CVD mortality but not WC in elderly women from the
UK.59 Elevated WHR was also independently associated
with a higher CVD risk in the Nurses’ Health Study and
in the Swedish Women’s Lifestyle and Health Cohort
Study.45 60 Women with a WHR of ≥0.88 were 3.25 times
more at risk of CHD compared with women with a WHR
of <0.72 after adjusting for BMI and other CVD risk
factors.45 Higher age-adjusted and sex-adjusted ORs
were also reported with WHR and CHD and CVD mor-
tality, compared with WC and BMI, in an Australian
population without heart disease, diabetes or stroke.61
Similar results were presented in other studies. WHR
reported the highest age standardised HRs in relation to
CVD mortality, followed by WSR, WC and BMI in
women.62 63 The advantages of WHR are: it has low
measurement error, high precision and no bias over a
wide range of ethnic groups.64 WHR, however, may not
be suitable for assessing central obesity in the elderly65
due to laxity of abdominal muscles which would under-
mine the predictive value of abdominal circumfer-
ences.55 It is also more difficult to measure than WC.37
Despite its limitations, WHR has been recommended for
incorporation into CVD risk assessment.37
WSR is the least commonly used measure of central
obesity. In a systematic review and meta-analysis study, WSR
reported the weakest correlations with CVD risk factors, com-
pared with BMI and other measures of central obesity,52
which is contrary to our study findings. In contrast, WSR was
most highly correlated with CHD risk predicted using the
Framingham model18 in women from England, compared
with BMI, WC and WHR in another study.66 WSR, however,
reported lower correlations than WC and BMI following
adjustments for age.66 The advantage of WSR is that the
same cut-point could be applied across a wide range of popu-
lations. A cut-off value of 0.5 indicates increased risk for men
and women and people of different ethnic groups, and this
Figure 1 ROC curves to compare the predictive ability of obesity measures for being above the 20% cut-off of three CVD
models: (A) Framingham risk score model for 10-year CVD incidence; (B) general cardiovascular disease risk score model for
10-year CVD incidence and death; (C) simplified general cardiovascular disease risk score model for 10-year CVD incidence and
death. #Area under the ROC curve is not calculated for this obesity measure as it contains height which is also used in the
calculation of the simplified general CVD model. BMI, body mass index; CVD, cardiovascular disease; ROC, receiver operating
characteristic; WC, waist circumference; WHR, waist-to-hip ratio; WSR, waist-to-stature ratio.
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value may also be used in children and adults, unlike WC
which requires different cut-offs.67 68 More research is
required to assess the association between WSR and CVD
risk in women, in comparison with WC, WHR and BMI.
Our study has limitations. This study is cross sectional;
however, it is a representative sample of the Australian
female population. There is only one set of baseline
measurements recorded for some risk variables but
important variables including anthropometric measures
of obesity are measured twice. Further, the 10-year CVD
risks are calculated using risk score models to stratify
individuals against the treatment thresholds of the
various models, and are not prospective CVD events.
CONCLUSIONS
Central obesity is more strongly associated with CVD risk
than general obesity. The deposition of adipose tissue is
associated with systemic inflammation which has a direct
effect on CVD risk. Therefore, increments in central
obesity have a more detrimental effect on CVD risk com-
pared with increments in general obesity.
When used alone, BMI is inadequate for identifying indivi-
duals at increased risk of CVD as it does not differentiate
between fat and fat-free mass. On the other hand, anthropo-
metric measurements of central obesity have higher sensitiv-
ity and specificity. These measures are also more sensitive to
lifestyle modifications. An increase in muscle mass through
diet and training would lead to changes in measures such as
WC and WSR but little change might be indicated with
BMI.69 It would be more useful to measure a patient’s
central obesity during clinical assessment to evaluate the
effect of lifestyle changes in relation to CVD risk compared
with BMI. Central obesity measures are also significant and
independent predictors of CVD risk, accounting for add-
itional risk above BMI. These measurements should be
incorporated into CVD risk assessment, particularly when
assessing the risk in women and the elderly.53 70–73
Future prospective studies are required to elucidate
which anthropometric measurements of central obesity
are better indicators or predictors of CVD risk.69 Studies
measuring body fat distribution using CT or MRI are
desirable to better understand the association between
body fat distribution and mortality, but are costly.74
In conclusion, WC, WHR and WSR, or measures of
central obesity that include a measurement of WC,
should be considered for incorporation into the clinical
assessment of CVD risk. Treatment of well-established
CVD risk factors coupled with reducing overweight and
obesity through lifestyle modifications would be an advis-
able goal in the primary prevention of CVD.4 It is
equally important to maintain a healthy weight and to
prevent central or abdominal obesity concurrently.
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